Role of Cytotoxic Therapy with Hematopoietic Cell Transplantation in the Treatment of Hodgkin Lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation

Perales, Miguel Angel; Ceberio, Izaskun; Armand, Philippe; Burns, Linda J.; Chen, Robert; Cole, Peter D.; Evens, Andrew M.; Laport, Ginna G.; Moskowitz, Craig H.; Popat, Uday; Reddy, Nishitha; Shea, Thomas C.; Vose, Julie M.; Schriber, Jeffrey; Savani, Bipin N.; Carpenter, Paul A.

doi:10.1016/j.bbmt.2015.02.022

Cited by 67 publications

(49 citation statements)

References 177 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The recently published guidelines of the American Society of Blood and Marrow Transplantation recommend allo-SCT as a preferred strategy over standard chemotherapy for relapse following auto-SCT 5 . This was a grade B recommendation due to the lack of adequate data and the sporadic nature of the available reports.…”

Section: Introductionmentioning

confidence: 99%

Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis

Rashidi

Ebadi

Cashen

2016

Bone Marrow Transplant

View full text Add to dashboard Cite

Allogeneic stem cell transplantation (allo-SCT) outcomes in patients with Hodgkin lymphoma (HL) remain poorly defined. We performed a meta-analysis of allo-SCT studies in HL patients. The primary endpoints were 6-month, 1-year, 2-year, and 3-year relapse-free survival (RFS) and overall survival (OS). A total of 42 reports (1,850 patients) were included. The pooled estimates (95%CI) for 6-month, 1-year, 2-year, and 3-year RFS were 77 (59–91)%, 50 (42–57)%, 37 (31–43)%, and 31 (25–37)%, respectively. The corresponding numbers for OS were 83 (75–91)%, 68 (62–74)%, 58 (52–64)%, and 50 (41–58)%, respectively. There was statistical heterogeneity among studies in all outcomes. In meta-regression, accrual initiation year in 2000 or later was associated with higher 6-month (P = 0.012) and 1-year OS (P = 0.046), and pre-SCT remission with higher 2-year OS (P = 0.047) and 1-year RFS (P = 0.016). In conclusion, outcomes of allo-SCT in HL have improved over time, with 5–10% lower non-relapse mortality and relapse rates and 15–20% higher RFS and OS in studies that initiated accrual in 2000 or later compared to earlier studies. However, there is no apparent survival plateau, demonstrating the need to improve on current allo-SCT strategies in relapsed/refractory HL.

show abstract

Section: Introductionmentioning

confidence: 99%

Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis

Rashidi

Ebadi

Cashen

2016

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Several studies examining the efficacy and safety of PD-1 inhibitors in combination with other agents, including the anti-CTLA4 antibody Ipilimumab and brentuximab vedotin (BV), are in progress and may further improve outcomes of patients with relapsed or refractory HL. However, autoHCT remains the standard of care for patients with relapsed HL responding to salvage therapy (6). …”

Section: Checkpoint Inhibition and Autohct (Table 1)mentioning

confidence: 99%

Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors

Ghosh

Politikos

Perales

2017

Current Opinion in Oncology

Self Cite

View full text Add to dashboard Cite

Purpose of review For several decades, hematopoietic cell transplantation has been considered the standard curative therapy for many patients with hematological malignancies. In addition to the cytotoxic effects of the chemotherapy and radiation used in the conditioning regimen, the benefits of hematopoietic cell transplantation are derived from a reset of the immune system and harnessing the ability of donor T cells to eliminate malignant cells. With the dawn of the era of immunotherapies in the form of checkpoint inhibitors and chimeric antigen receptor T cells, the role of hematopoietic cell transplantation has evolved. Recent findings Immunotherapy with checkpoint inhibitors is increasingly being used for relapsed Hodgkin and non-Hodgkin lymphoma after autoHCT. Checkpoint inhibitors are also being tested after alloHCT with observable benefits in treating hematological malignancies, but with a potential risk of increased GVHD and transplant-related mortality. Immunotherapy with CD19 CAR T cells are powerful options with aggressive B cell malignancies both for therapy and as induction leading to alloHCT. Summary While immunotherapies with checkpoint inhibition and CAR T cells are increasing being used to treat hematological malignancies, HCT remains a standard of care for most of the diseases with the best chance of cure. Combination of these therapies with HCT has the potential to more effectively treat hematological malignancies.

show abstract

“…Так, согласно российским клиническим рекомендациям (табл. 1) по диагностике и лечению злокачественных лимфопролиферативных за-болеваний (2016), а также рекомендациям EBMT (2010), ASBMT (American Society of Bone Marrow Transplantation, 2015) и NCCN (National Comprehensive Cancer Network, 2017), стандартом для выполнения процедуры является химиочувствительный рецидив [1,[8][9][10].…”

Section: Introductionunclassified

“…The median pretransplantation chemotherapy line was 3 (range [2][3][4][5][6][7][8][9]. At this stage, prior to auto-HSCT, complete remission (CR) rate was 26.5 %, partial remission (PR) rate was 52.3 %, disease stabilisation rate was 13.5 %.…”

mentioning

confidence: 98%

Outcome of Classical Hodgkin’s Lymphoma Treatment Based on HighDose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation: The Experience in the NI Pirogov Russian National Medical Center of Surgery

Мочкин

Саржевский

Dubinina

et al. 2018

Клиническая онкогематология

View full text Add to dashboard Cite

Aim. To estimate the long-term outcome of the programmed treatment of classical Hodgkin's lymphoma (cHL) including high-dose chemotherapy (HDCT) and autologous hematopoietic stem cell transplantation (auto-HSCT) as well as the effect of various factors on the achieved results in a singlecenter study. Materials & Methods. In the A.A. Maksimov Clinical Center of Hematology and Cellular Therapy of the NI Pirogov Russian National Medical Center of Surgery 260 cHL patients received HDCT combined with auto-HSCT within the period from December 2006 to March 2017. The median age was 29 years (range 17-62). The study included 40 % men (п = 104), and 60 % women (п = 156). The median pretransplantation chemotherapy line was 3 (range 2-9). At this stage, prior to auto-HSCT, complete remission (CR) rate was 26.5 %, partial remission (PR) rate was 52.3 %, disease stabilisation rate was 13.5 %. HDCT with auto-HSCT was applied beyond progression as a salvage therapy in 7.7 % of patients. In 79.6 % of patients the standard BEAM and CBV conditioning regimens were used. Results. After HDCT combined with auto-HSCT overall 5-year survival (OS) of 260 cHL patients was 74 %, and 5-year progression-free survival (PFS) was 48 %, which corresponds to the results of some international studies. 5-year OS rates were significantly higher after HDCT and auto-HSCT performed during the first CR or PR (85 %) vs the second and subsequent CR and PR (71 %). Neither gender (p = 0.4) nor ECOG status (p = 0.2) effects on OS and PFS were revealed. 5-year OS rates were significantly higher after HDCT and auto-HSCT performed during CR or PR (82 %) vs disease stabilisation and progression (54 %) as well as upon achieving CR (93 %) vs PR (77 %). Conclusion. In cHL tumor sensitivity to chemotherapy is the essential indication for HDCT combined with auto-HSCT. The optimal time for HDCT and auto-HSCT in cHL is the first CR/PR, and the best treatment outcome is achieved in patients with complete response prior to HDCT and auto-HSCT.

show abstract

Role of Cytotoxic Therapy with Hematopoietic Cell Transplantation in the Treatment of Hodgkin Lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation

Cited by 67 publications

References 177 publications

Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis

Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis

Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors

Outcome of Classical Hodgkin’s Lymphoma Treatment Based on HighDose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation: The Experience in the NI Pirogov Russian National Medical Center of Surgery

Contact Info

Product

Resources

About